References
- Slevin ML, Clark PI, Joel SP. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–1340
- Greco FA, Johnson DH, Hainsworth JD. Chronic oral etoposide. Cancer 1991; 67: 303–309
- Clark P, Cottier B, Joel S. Two prolonged schedules of single-agent oral etoposide of differing duration and dose in patients with untreated small-cell lung cancer. Proc Am Soc Clin Oncol 1991; 10: 268
- Johnson RK. Preclinical profile of SKF-104864, a water soluble camptothecin analog. Cancer Invest 1991; 9(3)346–347
- Burris HA, Hanauske A-R, Johnson RK. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816–1820
- Kunimoto T, Nitta K, Tanaka T. Antitumor activity of 7-ethyl-10-[4-(I-piperidino)-l-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944–5947
- Kawato Y, Furuta T, Aonuma M. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192–198
- Giovanella BC, Stehlin JS, Wall ME. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–1048
- Pantazis P, Hinz H, Mendoza J. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immuno-deficient mice induced by camptothecins. Cancer Res 1992; 52: 3980–3987
- Hsiang Y, Hertzberg RP, Hecht S. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–14878
- Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–374
- Zhang H, Drapa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990; 2: 23–27
- Capranico G, Zunino F. DNA topoisomerase-trapping antitumor drugs. Eur J Cancer 1992; 28A: 2055–2060
- Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834–2836
- Mattern MR, Mong S-M, Bartus HF. Relationship between the intracellular effects of camptothecin and the inhibition of topoisomerase I in cultured L1210 cells. Cancer Res 1987; 47: 1793–1798
- Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991; 193: 27–35
- Johnson RK, McCabe FL, Faucette LF. SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Cancer Res 1989; 30: 623
- Johnson RK, McCabe FL, Gallagher G. Comparative efficacy of topotecan, irinotecan, camptothecin, and 9-aminocamptothecin in preclinical tumor models. Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. 1992, 85
- Johnson RK, McCabe FL, Yu Y. Combination regimens with topotecan in animal tumor models. Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. 1992, 85
- Rowinsky EK, Grochow LB, Hendricks CB. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647–656
- Wall JA, Burris HA, Von Hoff DD. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor, topotecan (SK&F 104864), given as an intravenous bolus every 21 days. Anti-cancer Drugs 1992; 3: 337–345
- Kingsbury WD, Boehm JC, Jakas DR. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I activity and antitumor activity. J Med Chem 1991; 34: 98–107
- Schabel FM, Jr, Griswold DP, Jr, Laster WR, Jr. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1977; I: 411–435, Part A
- Houghton PJ, Cheshire PJ, Myers L. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31: 229–239
- Sirott MN, Saltz L, Young C. Phase I and clinical pharmacologic study of intravenous topotecan. Proc Am Soc Clin Oncol 1991; 10: 98
- Burris HA, Rothenberg ML, Kuhn JG. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992; 19: 663–669